Company intelligence / Profile preview
Charleston Laboratories, Inc.
Jupiter, Florida, United Statescharlestonlabs.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Charleston Laboratories completed two Phase 3 clinical trials for their lead product CL-108, a novel bi-layered tablet containing hydrocodone, acetaminophen, and promethazine. The company has resubmitted an NDA for CL-108. The first Phase 3 trial was conducted in patients following bunionectomy surgery, and the second was an open-label safety study in patients with osteoarthritis of the knee or hip.
- Therapeutic areas
- GastroenterologyOncologyNeurology
- Modalities
- Small moleculescombination drugs
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Daiichi Sankyo, Inc.
Beyond the preview
Go deeper on Charleston Laboratories, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Charleston Laboratories, Inc..